References
- Australian Public Assessment Report. (2009). Australian public assessment report for ziprasidone. Available from: https://www.tga.gov.au/file/1714/download. Accessed on March 17, 2016.
- Beedham C, Miceli JJ, Obach RS. (2003). Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol 23:229–232.
- Brambilla G, Mattioli F, Martelli A. (2009). Genotoxic and carcinogenic effects of antipsychotics and antidepressants. Toxicology 261:77–88.
- Darwish M, Bond M, Yang R, et al. (2014). Evaluation of the potential for a pharmacokinetic drug-drug interaction between armodafinil and ziprasidone in healthy adults. Clin Drug Investig 34:691–699.
- Eastmond DA, Tucker JD. (1989). Identification of aneuploidy inducing agents using cytokinesis-blocked human lymphocytes and an anti-kinetochore antibody. Environ Mol Mutagen 13:34–43.
- Evans HJ. (1984). Human peripheral blood lymphocytes for the analysis of chromosome aberrations in mutagen tests. In: Kilbey BJ, Legator M, Nichols W, Ramel C, eds. Handbook of mutagenicity test procedures. Amsterdam: Elsevier, 405–427.
- Fenech M. (2000). The in vitro micronucleus technique. Mutat Res 455:81–95.
- Fond G, Macgregor A, Attal J, et al. (2012). Antipsychotic drugs: Pro-cancer or anti-cancer? A systematic review. Med Hypotheses 79:38–42.
- Gomez-Criado MS, Bernardo M, de Florez T, et al. (2005). Ziprasidone overdose: cases recorded in the database of Pfizer-Spain and literature review. Pharmacotherapy 25:1660–1665.
- Karapidaki I, Ekonomopoulou MT, Akritopoulou K, et al. (2011). Cytogenetic effects of valproic acid and ziprasidone in human lymphocyte cultures. Neuropsychobiology 64:219–223.
- Katta K, Kandula VR, Rao TS, et al. (2015). Assessment and quantification of genotoxic impurities of Ziprasidone an antipsychotic drug. J Chem Pharm Res 7:739–750.
- Manini AF, Raspberry D, Hoffman RS, Nelson LS. (2007). QT prolongation and torsades de pointes following overdose of ziprasidone and amantadine. J Med Toxicol 3:178–181.
- Miao Z, Kamel A, Prakash C. (2005). Characterization of a novel metabolite intermediate of ziprasidone in hepatic cytosolic fractions of rat, dog, and human by ESI-MS/MS, hydrogen/deuterium exchange, and chemical derivatization. Drug Metab Dispos 33:879–883.
- National Institute for Occupational Safety and Health Drugs. (2012). NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2012. Available from: http://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf. Accessed on March 17, 2016.
- Prakash C, Kamel A, Cui D, et al. (2000). The metabolism of ziprasidone is complex and extensive. Br J Clin Pharmacol 49:35S–42S.
- Perry PE, Thompson EJ. (1984). The methodology of sister chromatid exchanges. In: Kilbey BJ, Legator M, Nichols W, Ramel C, eds. Handbook of mutagenicity test procedures. Amsterdam: Elsevier, 495–529.
- Physicians’ Desk Reference. (2005). Physicians’ desk reference (PDR), 59th ed. NJ, USA: Thomson PDR
- Schmidt AJ, Krieg JC, Clement HW, et al. (2010). Effects of quetiapine, risperidone, 9-hydroxyrisperidone and ziprasidone on the survival of human neuronal and immune cells in vitro. J. Psychopharmacol. (Oxford) 24:349–354.
- Sertie AL, Suzuki AM, Sertie RAL, et al. (2011). Effects of antipsychotics with different weight gain liabilities on human in vitro models of adipose tissue differentiation and metabolism. Prog Neuropsychopharmacol Biol Psychiatry 35:1884–1890.
- Snyder RD, Ewing D, Hendry LB. (2006). DNA intercalative potential of marketed drugs testing positive in in vitro cytogenetics assays. Mutat Res 609:47–59.
- Snyder RD, Holt PA, Maguire JM, Trent JO. (2013). Prediction of noncovalent drug/DNA interaction using computational docking models: studies with over 1350 launched drugs. Environ Mol Mutagen 54:668–681.
- Speit G, Haupter S. (1985). On the mechanism of differential giemsa staining of bromodeoxyuridine-substituted chromosomes. II. Differences between the demonstration of sister chromatid differentiation and replication patterns. Hum Genet 70:126–129.